Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DES (drug-eluting stent) study finds Cypher to be more cost-effective than Taxus:

This article was originally published in Clinica

Executive Summary

A German drug-eluting stent (DES) study has found that Johnson and Johnson's Cypher stent is more cost-effective than Boston Scientific's Taxus stent in patients at high risk of artery re-blockage. Sirolimus-eluting Cypher was associated with similar in-hospital costs, but significantly lower total costs at nine to 12 months compared with paclitaxel-eluting Taxus, according to the results, published in the Journal of the American College of Cardiology (July 18). "While health care costs and reimbursement rates vary between countries, these data suggest-that these cost differences are mainly due to the clinical benefits of the Cypher in reducing the need for a repeat procedure," said senior study author Dr Adnan Kastrati, of Deutsches Herzzentrum, in Munich. Specifically, total costs for Cypher and Taxus were Euro8,924 ($11,465) and Euro10,903, respectively.

You may also be interested in...

‘Supplement’ On CBD Product Label A Bullseye For US Litigants, Says Attorney

Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.

HBW Market News: GNC US Chief, Clasado Commercial Head, Barentz Funding

GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.

US Government Drug Pricing ‘Negotiation:’ Where We Go From Here

The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts